JP2015506961A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506961A5 JP2015506961A5 JP2014555801A JP2014555801A JP2015506961A5 JP 2015506961 A5 JP2015506961 A5 JP 2015506961A5 JP 2014555801 A JP2014555801 A JP 2014555801A JP 2014555801 A JP2014555801 A JP 2014555801A JP 2015506961 A5 JP2015506961 A5 JP 2015506961A5
- Authority
- JP
- Japan
- Prior art keywords
- renal cell
- cell carcinoma
- optionally
- therapeutic agent
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261593864P | 2012-02-02 | 2012-02-02 | |
| US61/593,864 | 2012-02-02 | ||
| US201261597124P | 2012-02-09 | 2012-02-09 | |
| US61/597,124 | 2012-02-09 | ||
| PCT/US2013/024510 WO2013116781A1 (en) | 2012-02-02 | 2013-02-01 | Alk1 antagonists and their uses in treating renal cell carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015506961A JP2015506961A (ja) | 2015-03-05 |
| JP2015506961A5 true JP2015506961A5 (enExample) | 2016-03-17 |
Family
ID=48903082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555801A Pending JP2015506961A (ja) | 2012-02-02 | 2013-02-01 | Ａｌｋ１アンタゴニストおよび腎細胞癌の治療におけるその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130202594A1 (enExample) |
| EP (1) | EP2809335A4 (enExample) |
| JP (1) | JP2015506961A (enExample) |
| KR (1) | KR20140123558A (enExample) |
| CN (1) | CN104321070A (enExample) |
| AU (1) | AU2013214779A1 (enExample) |
| BR (1) | BR112014019151A2 (enExample) |
| CA (1) | CA2863188A1 (enExample) |
| MX (1) | MX2014009277A (enExample) |
| RU (1) | RU2633638C2 (enExample) |
| WO (1) | WO2013116781A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170012582A (ko) | 2006-11-02 | 2017-02-02 | 악셀레론 파마 인코포레이티드 | Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도 |
| US10059756B2 (en) | 2006-11-02 | 2018-08-28 | Acceleron Pharma Inc. | Compositions comprising ALK1-ECD protein |
| US8642031B2 (en) | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
| AU2014388308A1 (en) * | 2014-03-28 | 2016-10-27 | Acceleron Pharma, Inc. | Use of activin receptor-like kinase 1 (ALK-1) antagonists in the treatment of cancer |
| JP2016036322A (ja) * | 2014-08-11 | 2016-03-22 | 日本化薬株式会社 | 血管新生因子と結合するキメラタンパク質 |
| WO2016144917A1 (en) * | 2015-03-10 | 2016-09-15 | University Of Massachusetts | Targeting gdf6 and bmp signaling for anti-melanoma therapy |
| SG11201707815RA (en) | 2015-06-05 | 2017-12-28 | Novartis Ag | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor |
| CN106994181A (zh) * | 2017-03-10 | 2017-08-01 | 上海交通大学医学院附属第九人民医院 | Bmp9在制备延缓肝纤维化药物中的应用 |
| KR102920712B1 (ko) | 2017-05-24 | 2026-01-30 | 노파르티스 아게 | 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법 |
| WO2019173482A1 (en) * | 2018-03-06 | 2019-09-12 | Sanford Burnham Prebys Medical Discovery Institute | 4-aminoquinoline compounds for the treatment of angiogenesis |
| US20250002588A1 (en) | 2023-04-07 | 2025-01-02 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8529014D0 (en) | 1985-11-25 | 1986-01-02 | Biogen Nv | Enhanced secretion of heterologous proteins |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US6858598B1 (en) * | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US20070105887A1 (en) * | 2005-11-04 | 2007-05-10 | Wyeth | Antineoplastic combinations of temsirolimus and sunitinib malate |
| EP2040738A1 (en) * | 2006-07-13 | 2009-04-01 | Zymogenetics, Inc. | Interleukin 21 and tyrosine kinase inhibitor combination therapy |
| KR20170012582A (ko) * | 2006-11-02 | 2017-02-02 | 악셀레론 파마 인코포레이티드 | Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도 |
| EP2150560A1 (en) * | 2007-06-01 | 2010-02-10 | Wyeth | Methods and compositions for modulating bmp-10 activity |
| CL2008003302A1 (es) * | 2007-11-09 | 2009-03-06 | Genentech Inc | Uso de una proteina de funsion kinasa 1 similar al receptor de activina (alk-1) y fc (alk1.fc) porque sirve para preparar un medicamento contra tumor,cancer o desordenes proliferativos. |
| WO2009128083A1 (en) * | 2008-04-16 | 2009-10-22 | Natco Pharma Limited | Novel polymorphic forms of sunitinib base |
| CN105963695A (zh) * | 2008-05-02 | 2016-09-28 | 阿塞勒隆制药公司 | 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物 |
| US7998973B2 (en) * | 2009-11-13 | 2011-08-16 | Aveo Pharmaceuticals, Inc. | Tivozanib and temsirolimus in combination |
| CA2796205A1 (en) * | 2010-04-15 | 2011-10-20 | Vegenics Pty Limited | Combination treatment with vegf-c antagonists |
-
2013
- 2013-02-01 WO PCT/US2013/024510 patent/WO2013116781A1/en not_active Ceased
- 2013-02-01 MX MX2014009277A patent/MX2014009277A/es unknown
- 2013-02-01 CN CN201380013788.3A patent/CN104321070A/zh active Pending
- 2013-02-01 RU RU2014134923A patent/RU2633638C2/ru not_active IP Right Cessation
- 2013-02-01 KR KR1020147024468A patent/KR20140123558A/ko not_active Withdrawn
- 2013-02-01 BR BR112014019151A patent/BR112014019151A2/pt not_active Application Discontinuation
- 2013-02-01 JP JP2014555801A patent/JP2015506961A/ja active Pending
- 2013-02-01 EP EP13744185.3A patent/EP2809335A4/en not_active Withdrawn
- 2013-02-01 US US13/757,672 patent/US20130202594A1/en not_active Abandoned
- 2013-02-01 CA CA2863188A patent/CA2863188A1/en not_active Abandoned
- 2013-02-01 AU AU2013214779A patent/AU2013214779A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jiang et al. | cGAS-STING, an important pathway in cancer immunotherapy | |
| JP7858715B2 (ja) | 高親和性のアイソフォーム選択的ＴＧＦβ１阻害剤、およびその使用 | |
| Peters et al. | Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects | |
| Procaccio et al. | Immunotherapy in gastrointestinal cancers | |
| Lu et al. | Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs | |
| Harris et al. | Immuno-oncology combinations: raising the tail of the survival curve | |
| Stern et al. | 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer | |
| Tartour et al. | Lung cancer: potential targets for immunotherapy | |
| CY1124791T1 (el) | Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων | |
| JP2016539096A5 (enExample) | ||
| JP2018515474A5 (enExample) | ||
| JP2021512914A5 (enExample) | ||
| RU2014134923A (ru) | Антагонисты alk1 и их применение в лечении почечно-клеточного рака | |
| Sun et al. | Immunotherapy in human colorectal cancer: challenges and prospective | |
| JP2016187356A5 (enExample) | ||
| Duarte et al. | Gastric cancer: basic aspects | |
| MX2021002190A (es) | Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20. | |
| JP2018501197A5 (enExample) | ||
| JP2016532693A5 (enExample) | ||
| JP2017506217A5 (enExample) | ||
| PH12012502193A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| WO2006038027A3 (en) | SINGLE DOMAIN ANTIBODIES AGAINST TNFRl AND METHODS OF USE THEREFOR | |
| WO2016191643A4 (en) | Tigit-binding agents and uses thereof | |
| JP2016537383A5 (enExample) | ||
| JP2017537972A5 (enExample) |